sutimlimab-jome
sutimlimab-jome is listed in the FDA National Drug Code directory with 1 NDC code, marketed under brand name including Enjaymo. Available dosage form: injection, solution, concentrate.
Drug Details
- Generic Name
- sutimlimab-jome
- Brand Names
- Enjaymo
- Application Number
- BLA761164
- Sponsor
- Recordati Rare Diseases, Inc.
- NDC Codes
- 1
- Dosage Forms
- INJECTION, SOLUTION, CONCENTRATE
- Routes
- INTRAVENOUS
- Active Ingredients
- SUTIMLIMAB
Indications and Usage
1 INDICATIONS AND USAGE ENJAYMO is a classical complement inhibitor indicated for the treatment of hemolysis in adults with cold agglutinin disease (CAD). ( 1 ) Cold Agglutinin Disease ENJAYMO (sutimlimab-jome) is indicated for the treatment of hemolysis in adults with cold agglutinin disease (CAD).